Concepedia

Katie Wood

KW

Statistics

Publications

10

Citations

365

H-Index

10

Active since

1957

Affiliations

Sarah Cannon(Current)

Tennessee Oncology

The University of Texas Southwestern Medical Center

University of Oklahoma Health Sciences Center

Harvard University

Katie Wood is an author at Sarah Cannon specializing in oncology, antibody-drug conjugate therapy, and chemotherapy.

Publications per year

1957–2019

10

Publications

10

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

J.F. Liu, Kathleen N. Moore, Michael J. Birrer et al. · Annals of Oncology · 2016 · 140 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

David E. Gerber, Jeffrey R. Infante, Michael S. Gordon et al. · Clinical Cancer Research · 2019 · 53 citations

Medicine, Oncology, Pharmacology +17

Shiga Toxin 2 Causes Apoptosis in Human Brain Microvascular Endothelial Cells via C/EBP Homologous Protein

Jun Fujii, Katie Wood, Fumiko Matsuda et al. · Infection and Immunity · 2008 · 51 citations

Life Sciences, Cell Biology, Molecular Biology +17

Dangerous Bleeding Associated with Carcinoma of Prostate

Henry Swan, Katie Wood, Owen Daniel · BMJ · 1957 · 33 citations · Full text

Medicine, Oncology, Urology +12

A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC).

Howard A. Burris, Michael S. Gordon, David E. Gerber et al. · Journal of Clinical Oncology · 2014 · 26 citations

Medicine, Oncology, Pharmacology +14

1–5 of 10